• 13 DE
• 14 EN

• 9 Home
• 10 Contact
• 11 Sitemap

• 7 Press
  • 7.1 Press Releases
    • 7.1.1 Company
      • 7.1.1.1 2000
      • 7.1.1.2 2001
      • 7.1.1.3 2002
      • 7.1.1.4 2003
      • 7.1.1.5 2004
      • 7.1.1.6 2005
      • 7.1.1.7 2006
      • 7.1.1.8 2007
      • 7.1.1.9 2008
    • 7.1.2 Health
  • 7.2 Photos & Logos

Change in Management in Global Research & Development at Merz Pharmaceuticals

Frankfurt am Main, 24.07.2006

Dr. Alexander Gebauer has assumed responsibility for Global R & D Pharmaceuticals effective July 1, 2006. Gebauer succeeds Dr. Hans Jörg Möbius, who will be leaving the Merz Group and his position as Managing Director of Merz Pharmaceuticals GmbH.

Alexander Gebauer, MD, has many years of experience in the industry. Before joining Merz in 2005, he held various management positions in preclinical and clinical research at Sanofi-Aventis and its predecessor companies.

“Alexander Gebauer is an exceptionally qualified person for the position,” said Dr. Martin Zügel, CEO of Merz Pharmaceuticals GmbH. “His experience in the expansion of successful product pipelines in particular will be of tremendous benefit to us. Focused research and development are one of the highest priorities at Merz, today and in the future.”

Dr. Hans Jörg Möbius, who will be leaving Merz after more than ten years, will continue to assist the company in an advisory capacity. The Research & Development department was systematically expanded under his management. He successfully promoted a number of projects and processes, most recently the worldwide approval of memantine (Axura®) and the approval of von Xeomin in Germany.

About Merz Pharmaceuticals (www.merz.de):

Merz Pharmaceuticals, headquartered in Frankfurt, Germany, is an international pharmaceutical company specializing in research and development of pharmaceuticals for the treatment of neurological and psychiatric diseases. Merz Pharmaceuticals is a leader in the field of Alzheimer research and developed memantine as the only drug approved worldwide for the treatment of moderate to severe Alzheimer’s disease. Other indications researched by Merz Pharmaceuticals are dermatology and metabolic diseases.

Contact:

Merz Pharma GmbH & Co. KGaA
Corporate Communications
Eckenheimer Landstraße 100
60318 Frankfurt
Phone: 069 / 15 03 - 889
Fax: 069 / 15 03 - 400
E-Mail: presse@merz.de

• 0.1 A-
• 0.2 A
• 0.3 A+
• 0.4 Print

Search

Search

Search

Login for Professionals

Login for Professionals

Merz DocCheck User Password

new user

German Websites

• Alzheimer´s
• Depression
• Dystonia
• Hair Loss
• Hyal-System
• Liver Disease
• Parkinson´s